Evidence map›Paper›PMID 35371561›Full record

ArticleVirus evolution2022

The early SARS-CoV-2 epidemic in Senegal was driven by the local emergence of B.1.416 and the introduction of B.1.1.420 from Europe.

Lester J Perez, Gregory S Orf, Michael G Berg, Mary A Rodgers, Todd V Meyer, Aurash Mohaimani, Ana Olivo, Barbara Harris, Illya Mowerman, Abdou Padane and 8 more

Abstract read
In one paragraph

Article in Virus evolution, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Lester J PerezInfectious Disease Core Research, Abbott Diagnostics Division, Abbott Laboratories, 100 Abbott Park Rd, Lake Bluff, IL 60044, USA.
Gregory S OrfInfectious Disease Core Research, Abbott Diagnostics Division, Abbott Laboratories, 100 Abbott Park Rd, Lake Bluff, IL 60044, USA.
Michael G BergInfectious Disease Core Research, Abbott Diagnostics Division, Abbott Laboratories, 100 Abbott Park Rd, Lake Bluff, IL 60044, USA.
Mary A RodgersInfectious Disease Core Research, Abbott Diagnostics Division, Abbott Laboratories, 100 Abbott Park Rd, Lake Bluff, IL 60044, USA.
Todd V MeyerInfectious Disease Core Research, Abbott Diagnostics Division, Abbott Laboratories, 100 Abbott Park Rd, Lake Bluff, IL 60044, USA.
Aurash MohaimaniInfectious Disease Core Research, Abbott Diagnostics Division, Abbott Laboratories, 100 Abbott Park Rd, Lake Bluff, IL 60044, USA.
Ana OlivoInfectious Disease Core Research, Abbott Diagnostics Division, Abbott Laboratories, 100 Abbott Park Rd, Lake Bluff, IL 60044, USA.
Barbara HarrisInfectious Disease Core Research, Abbott Diagnostics Division, Abbott Laboratories, 100 Abbott Park Rd, Lake Bluff, IL 60044, USA.
Illya MowermanInfectious Disease Core Research, Abbott Diagnostics Division, Abbott Laboratories, 100 Abbott Park Rd, Lake Bluff, IL 60044, USA.
Abdou PadaneInstitut de Recherche en Santé de Surveillance Épidémiologique et de Formation, 4 Rue 2 D1 Pole Urbain de Diamniado, Dakar BP 7325, Senegal.
Agbogbenkou Tevi Dela-Del LawsonInstitut de Recherche en Santé de Surveillance Épidémiologique et de Formation, 4 Rue 2 D1 Pole Urbain de Diamniado, Dakar BP 7325, Senegal.
Aminata MboupInstitut de Recherche en Santé de Surveillance Épidémiologique et de Formation, 4 Rue 2 D1 Pole Urbain de Diamniado, Dakar BP 7325, Senegal.
Moustapha MbowInstitut de Recherche en Santé de Surveillance Épidémiologique et de Formation, 4 Rue 2 D1 Pole Urbain de Diamniado, Dakar BP 7325, Senegal.
Nafissatou LeyeInstitut de Recherche en Santé de Surveillance Épidémiologique et de Formation, 4 Rue 2 D1 Pole Urbain de Diamniado, Dakar BP 7325, Senegal.
Ndeye Coumba Touré-KaneInstitut de Recherche en Santé de Surveillance Épidémiologique et de Formation, 4 Rue 2 D1 Pole Urbain de Diamniado, Dakar BP 7325, Senegal.
Ambroise D AhouidiInstitut de Recherche en Santé de Surveillance Épidémiologique et de Formation, 4 Rue 2 D1 Pole Urbain de Diamniado, Dakar BP 7325, Senegal.
Gavin A ClohertyInfectious Disease Core Research, Abbott Diagnostics Division, Abbott Laboratories, 100 Abbott Park Rd, Lake Bluff, IL 60044, USA.
Souleymane MboupInstitut de Recherche en Santé de Surveillance Épidémiologique et de Formation, 4 Rue 2 D1 Pole Urbain de Diamniado, Dakar BP 7325, Senegal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Molecular surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is growing in west Africa, especially in the Republic of Senegal. Here, we present a molecular epidemiology study of the early waves of SARS-CoV-2 infections in this country based on Bayesian phylogeographic approaches. Whereas the first wave in mid-2020 was characterized by a significant diversification of lineages and predominance of B.1.416, the second wave in late 2020 was composed primarily of B.1.1.420. Our results indicate that B.1.416 originated in Senegal and was exported mainly to Europe. In contrast, B.1.1.420 was introduced from Italy, gained fitness in Senegal, and then spread worldwide. Since both B.1.416 and B.1.1.420 lineages carry several positive selected mutations in the spike and nucleocapsid genes, each of which may explain their local dominance, their mutation profiles should be carefully monitored. As the pandemic continues to evolve, molecular surveillance in all regions of Africa will play a key role in stemming its spread.

Indexed as

Bayesian inference of phylogenyphylogeographypositive selection analysisSARS-CoV-2Senegalvariants of interestviral surveillance

Identifiers

PMID35371561
PMCPMC8971539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.